Content and data provided by various third parties and Fidelity − Terms of Use | Help/Glossary
Research > ETFs > ETF / ETP Commentary > 

Healthcare Rules State Street's Top 5 ETFs in Past Month

BY | ETF Database
10:48 am ET 07/17/26 | 12 VIEWS
With well over 170 ETFs on the market covering diverse investment strategies, State Street offers a prime window into which funds — and market trends — are leading the pack in the near term.Key Takeaways: Across State Street’s 170+ ETFs, the top five performers this past month are all tied to the healthcare industry. Specific areas of healthcare include: biotechnology, healthcare equipment, and insurance, among others The State Street SPDR S&P Pharmaceuticals ETF (XPH B+) was the top performer with returns of 11.69% within the one-month period. To see where the market momentum lies, we analyzed State Street’s top five performing ETFs over the one-month period spanning June 16 to July 16, 2026. Many would assume that any overarching theme attributed to these top five would likely be tech or AI.  However, this was not the case — State Street’s top five ETFs were largely tied to the healthcare industryState Street's Top 5: Healthcare's Summer RemedyIn fifth place, the State Street SPDR S&P Health Care Equipment ETF (XHE A-) captured an 8.72% gain over the past month. The fund offers tactical exposure to companies engaged in healthcare supplies and equipment.  Next on the list is the State Street SPDR S&P Insurance ETF (KIE A-) with a 9.12% gain over the period. KIE invests in a variety of insurance companies, such as insurance brokers, health insurance, property & casualty insurance, and others.  Sitting in third place is the State Street SPDR S&P Health Care Services ETF (XHS B+), which saw a 10.78% return this month. The fund offers focused exposure to specified areas, including healthcare distributors, healthcare services, healthcare facilities, and managed healthcare.  See More: Q2 Earnings Preview: Tech & Energy Drive Growth Amid Healthcare Headwinds  The State Street SPDR S&P Biotech ETF (XBI A) was the second top performer, gaining 11.54% over the one-month period. True to its name, XBI offers investors targeted access to companies within the biotech industry. Pharmaceuticals Top State Street's ETF SuiteSecuring the top spot, the State Street SPDR S&P Pharmaceuticals ETF (XPH B+) surged 11.69% from June 16 to July 16, 2026. The fund delivers targeted exposure to the pharmaceutical industry, drawing strong interest from the broader investment community. As of July 15, 2026, XPH has attracted over $160 million in net year-to-date inflows. While State Street’s diverse ETF lineup accommodates all sectors and strategies, investors may want to consider these recent metrics. The healthcare industry is presenting clear opportunities right now and State Street is offering a variety of compelling ways to target them.  For more news, information, and analysis, visit the Equity ETF Content Hub.

More Commentary

Use These ETFs as Health Stocks LLY, UNH, MRK Thrive
BY | ETF Database
6:19 am ET 07/17/26 | 21 VIEWS
The Structured Credit Advantage: High Yields, Low Defaults
BY | ETF Database
7:02 am ET 07/17/26 | 22 VIEWS
Single-Country Swagger: Capture Localized Alpha With These ETFs
BY | ETF Database
5:19 am ET 07/17/26 | 19 VIEWS
View more Commentary

Search Commentary

Enter Keyword(s)
Filter Results

Performance data shown is past performance and is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore you have a gain or loss when you sell your shares. For standard quarterly performance, go to the fund's Snapshot page by clicking on the ETF/ETP's symbol.

ETFs may trade at a premium or discount to their NAV and are subject to the market fluctuations of their underlying investments.

For iShares ETFs, Fidelity receives compensation from the ETF sponsor and/or its affiliates in connection with an exclusive long-term marketing program that includes promotion of iShares ETFs and inclusion of iShares funds in certain FBS platforms and investment programs. Please note, this security will not be marginable for 30 days from the settlement date, at which time it will automatically become eligible for margin collateral. Additional information about the sources, amounts, and terms of compensation can be found in the ETF's prospectus and related documents. Fidelity may add or waive commissions on ETFs without prior notice. BlackRock and iShares are registered trademarks of BlackRock, Inc. and its affiliates.

FBS receives compensation from the fund's advisor or its affiliates in connection with a marketing program that includes the promotion of this security and other ETFs to customers ("Marketing Program"). The Marketing Program creates incentives for FBS to encourage the purchase of certain ETFs. Additional information about the sources, amounts, and terms of compensation is in the ETF's prospectus and related documents. Please note that this security will not be marginable for 30 days from the settlement date, at which time it will automatically become eligible for margin collateral.

News, commentary (including "Related Symbols") and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended to help self-directed investors evaluate exchange traded products (ETPs), including, but limited to exchange traded funds (ETFs) and exchange traded notes (ETNs). Criteria and inputs entered, including the choice to make ETP comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a particular security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating ETPs. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use. Determine which securities are right for you based on your investment objectives, risk tolerance, financial situation and other individual factors and re-evaluate them on a periodic basis.

Before investing in any exchange traded product, you should consider its investment objective, risks, charges and expenses. Contact Fidelity for a prospectus, offering circular or, if available, a summary prospectus containing this information. Read it carefully.